Liquid-filled capsules are no longer a specialized workaround but a technically sophisticated platform that demands deliberate alignment among formulation design, manufacturing capability and quality strategies.
As small molecule pipelines continue to shift toward more complex, potent and sensitive APIs and as clinical trials similarly evolve toward greater complexity, the linear model of development is no longer sufficiently robust. Instead, success depends on a thoughtful integration of formulation science, specialized filling capabilities and clinical supply planning.
Machinability issues linked to capsule-related factors can disrupt production, increase waste and jeopardize delivery timelines.
Recent advances are turning what was once a trial-and-error exercise into a disciplined and reproducible design workflow.
As material complexity and regulatory expectations grow, LD-PCRS correlative characterization will support robust formulation design, process control, and risk-based decision-making.
Process instability in solid-dose manufacturing rarely appears suddenly. More often, it shows up as gradual drift: weight variability increases, density becomes less consistent, deviations rise, and output slows. Root-cause investigations begin — and one contributing factor is often underestimated is feeder platform leveling.
If history tells us anything, it’s this: in drug delivery, progress doesn’t come in bursts. It flows — steady, adaptable and always moving forward.